NYSE: CON · Medical Care Facilities

Concentra Group Holdings Parent (CON) fair value: undervalued or overvalued?

As of 16 Nov 2026, Faircurve's model values Concentra Group Holdings Parent (CON) at $43.92 a share. The stock last closed at $43.44, which puts the model's fair value 1.1% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Concentra Group Holdings Parent, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$43.92midpoint of 2,000 simulations
Last close$43.44NYSE: CON
Gap to fair value+1.1%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 16 Nov 2026 moved the fair value from $46.11 to $43.92 (-4.7%). Net debt rose on the latest balance sheet: most of the move.

What the model makes of itThe price of $43.44 is 1.1% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 25 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give CON?

The calibrated range for CON over 63 trading days is $35.12 to $52.18. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $32.51 to $57.73. In 54% of the simulations the fair value came out above the price the model ran on.

$20.82$81.36
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $43.92. Dashed line: the last close, $43.44.

Faircurve Insights · 16 Nov 2026

Concentra Group Holdings Parent, Inc. (CON) is a U.S.-based provider of occupational health solutions. It sits in Healthcare, Medical Care Facilities.

Faircurve's model put the fair value at $43.92 a share on 16 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $46.11, so the fair value moved -4.7%. The model's reason: Net debt rose on the latest balance sheet, which was most of the move. The calibrated range over 63 trading days is $35.12 to $52.18. It is built from the fair value, since there is no live options data for the stock, and calibrated weekly against realised prices (13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It looks at input completeness, the number of comparable companies and how closely they agree, and the width of the range. It does not say whether the fair value is right.

Faircurve's model gives the business an overall quality score of 66 out of 100, against comparable companies. Two factors stand out. Balance sheet scores 23, with net debt to EBITDA at 4.27x against a peer median of 1.39x. Stability scores 88, with EBITDA margin downside volatility at 0.6 pts over five years against a peer median of 1.0 pts. The model compares the company with Option Care Health, Hims & Hers Health, Chemed, Universal Health Services, DaVita and The Ensign Group.

Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does CON report earnings, and how has the stock reacted?

Concentra Group Holdings Parent's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CON's last 8 reports, ignoring direction, was 3.2%.

0%5%10%15%no quote3.4%31 Oct '24no quote0.6%3 Mar '25no quote8.4%7 Aug '25no quote1.0%6 Nov '25no quote0.3%28 Jan '26no quote5.9%7 May '26no quote10.7%6 Aug '2612.5%3.1%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

How does CON score on business quality?

Concentra Group Holdings Parent's overall quality score is 66 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.6711.7%ROIC8.9%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).811.19xFCF / net income1.08x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.5813.9%Revenue growth, trailing17.8%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.701.1%Net buybacks / market value0.3%
Balance sheetNet debt to EBITDA and interest coverage.234.27xNet debt / EBITDA1.39x
StabilityDownside volatility of the EBITDA margin over the last five years.880.6 ptsEBITDA margin downside volatility, 5y1.0 pts

How does CON compare with similar companies?

The companies in medical care facilities closest to Concentra Group Holdings Parent in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
OPCH Option Care Health, Inc.$31.71$32.92+3.8%Fairly valued
HIMS Hims & Hers Health, Inc.$18.56$21.46+15.6%Undervalued
CHE Chemed Corporation$549.45$568.98+3.6%Fairly valued
ACHC Acadia Healthcare Company, Inc.$38.70$44.44+14.8%Low evidence grade
NHC National HealthCare Corporation$207.19$249.00+20.2%Low evidence grade
UHS Universal Health Services, Inc.$197.80$310.03+56.7%Undervalued
DVA DaVita Inc.$174.22$212.79+22.1%Undervalued
ENSG The Ensign Group, Inc.$188.23$174.98-7.0%Fairly valued

What the comparable companies' multiples alone would give for CON, the peer-implied price, is $51.08 a share on this run. The fair value weighs that against the company's own multiple.

All medical care facilities stocks ranked by gap to fair value

Concentra Group Holdings Parent at a glance

Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions.

Market value
$5.4B
Sector
Healthcare
Industry
Medical Care Facilities
Revenue expected, next twelve months
$2.5B
Consensus revenue growth, next fiscal year
+9.4%
Analysts with estimates
6
Beta to the US market
0.41
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CON was among them.

How the fair value is worked out: the model prices Concentra Group Holdings Parent on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for CON was $46.11. As of 16 Nov 2026 it is $43.92, a change of -4.7%. Net debt rose on the latest balance sheet: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Concentra Group Holdings Parent's valuation

Is Concentra Group Holdings Parent stock undervalued or overvalued?

On Faircurve's model, CON reads as Fairly valued as of 16 Nov 2026. The model's fair value is $43.92 a share against a last close of $43.44, a gap of +1.1%.

What is CON's fair value?

$43.92 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $32.51 to $57.73.

What price range does the model give CON?

$35.12 to $52.18 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.

When does Concentra Group Holdings Parent report earnings next?

The next report is scheduled for 25 Feb 2027. Companies can move their dates.

How much has CON moved on past earnings reports?

Across its last 8 reports the median two session move was 3.2%, ignoring direction. The largest was +10.7% around the report of 6 Aug 2026.

How confident is the model in this valuation?

The model's evidence grade for CON is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on CON

The model holds no idea open on CON today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CON with their outcomes. A free account is enough.

Keep reading